Vinpocetine
Vinpocetine structure
|
Common Name | Vinpocetine | ||
|---|---|---|---|---|
| CAS Number | 42971-09-5 | Molecular Weight | 350.454 | |
| Density | 1.3±0.1 g/cm3 | Boiling Point | 419.5±45.0 °C at 760 mmHg | |
| Molecular Formula | C22H26N2O2 | Melting Point | 147-153ºC dec | |
| MSDS | Chinese USA | Flash Point | 207.5±28.7 °C | |
| Symbol |
GHS07 |
Signal Word | Warning | |
|
Vinpocetine and α-tocopherol prevent the increase in DA and oxidative stress induced by 3-NPA in striatum isolated nerve endings.
J. Neurochem. 124(2) , 233-40, (2013) Vinpocetine is a neuroprotective drug that exerts beneficial effects on neurological symptoms and cerebrovascular disease. 3-nitropropionic acid (3-NPA) is a toxin that irreversibly inhibits succinate dehydrogenase, the mitochondrial enzyme that acts in the e... |
|
|
[Current possibilities of the correction of oxidative stress in acute brain ischaemia].
Zh. Nevrol. Psikhiatr. Im. S. S. Korsakova 112(11) , 79-82, (2012)
|
|
|
Piracetam and vinpocetine ameliorate rotenone-induced Parkinsonism in rats.
Indian J. Pharmacol. 44(6) , 774-9, (2012) To evaluate the neuroprotective effect of the nootropic drugs, piracetam (PIR) and vinpocetine (VIN), in rotenone-induced Parkinsonism in rats.Sixty male rats were divided into 6 groups of 10 rats each. The groups were administered vehicle, control (rotenone,... |
|
|
Behavioral effects of family-selective inhibitors of cyclic nucleotide phosphodiesterases.
Pharmacol. Biochem. Behav. 63 , 185-192, (1999) The effects of family selective inhibitors of phosphodiesterase (PDEI, PDE2, PDE3, PDE4, and PDE5) on the behavior of rats under either a differential-reinforcement-of-low-rate (DRL) 72-s schedule or a variable-interval (VI) 30-s schedule were determined; pre... |
|
|
The calcium/calmodulin-dependent phosphodiesterase PDE1C down-regulates glucose-induced insulin secretion.
J. Biol. Chem. 274 , 22337-22344, (1999) To understand the role cAMP phosphodiesterases (PDEs) play in the regulation of insulin secretion, we analyzed cyclic nucleotide PDEs of a pancreatic beta-cell line and used family and isozyme-specific PDE inhibitors to identify the PDEs that counteract gluco... |
|
|
Involvement of phosphodiesterase-cGMP-PKG pathway in intracellular Ca2+ oscillations in pituitary GH3 cells.
Biochim. Biophys. Acta 1449 , 186-193, (1999) The present study investigates the potential role of the Ca2+-calmodulin-dependent type I phosphodiesterase (PDE)-cGMP-protein kinase G (PKG) pathway in spontaneous [Ca2+]i oscillations in GH3 cells using fura-2 single cell videoimaging. Vinpocetine (2.5-50 m... |
|
|
Evolution of microglial activation in ischaemic core and peri-infarct regions after stroke: a PET study with the TSPO molecular imaging biomarker [((11))C]vinpocetine.
J. Neurol. Sci. 320(1-2) , 110-7, (2012) Although there is increasing evidence for microglial activation after an ischaemic stroke in the infarct core and the peri-infarct region, the "evolution" of the process in stroke patients is poorly known. Using PET and [((11))C]vinpocetine, we measured the r... |
|
|
[The neurologists's view of the etiology and treatment of sensorineural hearing impairment].
Vestn. Otorinolaringol. (1) , 85-7, (2013) The present paper is focused on the problem of etiology of sensorineural hearing impairment, approaches to its treatment, and actions to be taken by a physician to manage the disease. Sensorineural hearing impairment is considered to be a challenging socio-me... |
|
|
TSPO-specific ligand vinpocetine exerts a neuroprotective effect by suppressing microglial inflammation.
Neuron Glia Biol. 7(2-4) , 187-97, (2011) Vinpocetine has long been used for cerebrovascular disorders and cognitive impairment. Based on the evidence that the translocator protein (TSPO, 18 kDa) was expressed in activated microglia, while Vinpocetine was able to bind TSPO, we explored the role of Vi... |
|
|
[The observation on curative effect of 90 cases of sudden hearing loss].
Lin Chuang Er Bi Yan Hou Ke Za Zhi 26(7) , 306-8, (2012) To evaluate the efficiency between two treatments of sudden hearing loss.All patients were divided into two groups randomly, basic drug group was treated with ganglioside and vinpocetine injection, combined therapy group was treated with intratympanic dexamet... |